Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cocrystal Pharma, Inc.COCP · Entity 7621 | 10% owner | May 04, 2021 | May 06, 2021 |
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Director | May 10, 2022 | May 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cocrystal Pharma, Inc.
Report date May 04, 2021 · Filed May 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,674,960 |
Reported balance
After 2021-05-04 transaction · row 1
1 source rowRow 1 · 2021-05-04 · Sale · Disposed 575,000 · Balance 7,674,960 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.60 to $3.25, inclusive. The Reporting Person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.60 to $3.25, inclusive. The Reporting Person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in footnote (1) to this Form 4.
PRECISION BIOSCIENCES INC
Report date May 10, 2022 · Filed May 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2032-05-09 | Direct | 156,951 |
Reported balance
After 2022-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-10 · Grant · Acquired 156,951 · Balance 156,951 F1: The option vests on the earlier to occur of (i) May 10, 2023 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier to occur of (i) May 10, 2023 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2022 Filed May 12, 2022 11:13 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantStock Option (Right to Buy) · Derivative | 156,951 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-22-028445 · doc4.xml · derivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,951 Underlying: Common Stock · 156,951 shares Expires 2032-05-09 F1 · derivative.exercise_date: The option vests on the earlier to occur of (i) May 10, 2023 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:07 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantStock Option (Right to Buy) · Derivative | 32,800 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001209191-21-032018 · doc4.xml · derivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 22:00 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | SaleCommon Stock | 575,000 | $2.95 | $1,696,250.00 |
DisclosureSEC source: 0001493152-21-010669 · ownership.xml · nonDerivative · entry 1 Schinazi Raymond F · CIK 0001397607 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,674,960 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.60 to $3.25, inclusive. The Reporting Person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantStock Option (Right to Buy) · Derivative | 41,038 | $0.00 Strike: $6.62 | $0.00 |
DisclosureSEC source: 0001209191-20-029688 · doc4.xml · derivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,038 Underlying: Common Stock · 41,038 shares Expires 2030-05-12 F1 · derivative.exercise_date: The option vests on the earlier of May 13, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 13, 2020. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 21:03 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | PurchaseCommon Stock | 7,906 | $1.15 | $9,091.90 |
DisclosureSEC source: 0001493152-19-016105 · ownership.xml · nonDerivative · entry 3 Schinazi Raymond F · CIK 0001397607 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,257,863 Read SEC document |
| October 24, 2019 Filed Oct 29, 2019 21:03 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | PurchaseCommon Stock | 5,094 | $1.15 | $5,858.10 |
DisclosureSEC source: 0001493152-19-016105 · ownership.xml · nonDerivative · entry 2 Schinazi Raymond F · CIK 0001397607 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,249,957 Read SEC document |
| October 23, 2019 Filed Oct 29, 2019 21:03 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | PurchaseCommon Stock | 3,935 | $1.04 | $4,086.89 |
DisclosureSEC source: 0001493152-19-016105 · ownership.xml · nonDerivative · entry 1 Schinazi Raymond F · CIK 0001397607 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,244,863 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.965 to $1.08, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the footnote of this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:19 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | ConversionSeries B Preferred Stock · Derivative | 119,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-022658 · doc4.xml · derivative · entry 4 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RFS Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 56,102 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO"). F2 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO"). F2 · derivative.exercise_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO"). F2 · derivative.expiration_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO"). F1 · ownership.nature: The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:19 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | ConversionConvertible Promissory Note · Derivative | Not disclosed | Not disclosed Strike: $13.60 | $502,466.00 |
DisclosureSEC source: 0001209191-19-022658 · doc4.xml · derivative · entry 3 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RFS Partners, LP Disclosed balance after: 0 Underlying: Common Stock · 36,946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO. F3 · derivative.exercise_date: On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO. F3 · derivative.expiration_date: On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO. F1 · ownership.nature: The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:19 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | ConversionCommon Stock | 56,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-022658 · doc4.xml · nonDerivative · entry 2 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RFS Partners, LP Disclosed balance after: 93,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO"). F1 · ownership.nature: The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:19 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | ConversionCommon Stock | 36,946 | $13.60 | $502,465.60 |
DisclosureSEC source: 0001209191-19-022658 · doc4.xml · nonDerivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RFS Partners, LP Disclosed balance after: 36,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 22:36 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | OtherConvertible Promissory Note · Derivative | Not disclosed | $500,000.00 Strike: $13.60 | $502,466.00 |
DisclosureSEC source: 0001209191-19-021848 · doc4.xml · derivative · entry 2 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RFS Partners, LP Disclosed balance after: Not disclosed Underlying: Common Stock · 36,946 shares Expires not disclosed F2 · kind: On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO. F2 · derivative.exercise_date: On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO. F2 · derivative.expiration_date: On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO. F3 · ownership.nature: The 2019 Note is held of record by RFS. RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 22:36 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantStock Option (Right to Buy) · Derivative | 34,544 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021848 · doc4.xml · derivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,544 Underlying: Common Stock · 34,544 shares Expires 2029-03-26 F1 · derivative.exercise_date: The option vests as to 34% of the underlying shares on March 27, 2020 and vests in equal installments at the end of each successive three-month period over the following 24 months. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 20:43 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001493152-18-013665 · ownership.xml · derivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments. Read SEC document |
| May 10, 2018 Filed May 14, 2018 20:01 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | Exercise / conversion8% Convertible Note · Derivative | 263,158 | $500,000.00 Strike: $1.90 | $131,579,000,000.00 |
DisclosureSEC source: 0001493152-18-006784 · form4.xml · derivative · entry 6 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 263,158 Underlying: Common Stock · 263,158 shares Expires 2019-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018. Read SEC document |
| May 10, 2018 Filed May 14, 2018 20:01 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | Grant8% Convertible Note · Derivative | 263,158 | $500,000.00 Strike: $1.90 | $131,579,000,000.00 |
DisclosureSEC source: 0001493152-18-006784 · form4.xml · derivative · entry 5 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 263,158 Underlying: Common Stock · 263,158 shares Expires 2019-11-24 F1 · security: The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018. F4 · security: In accordance with Rule 16b-3, in advance of the effectuation of the transactions reported, the issuer's board of directors approved an amendment to the convertible note held by the reporting person who is a director and 10% beneficial owner of the issuer. The amendment of the outstanding convertible note is reported as a cancellation of the "old" note and the grant of a replacement note. Read SEC document |
| May 10, 2018 Filed May 14, 2018 20:01 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | Disposition to issuer8% Convertible Note · Derivative | 61,728 | $500,000.00 Strike: $8.10 | $30,864,000,000.00 |
DisclosureSEC source: 0001493152-18-006784 · form4.xml · derivative · entry 4 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 61,728 Underlying: Common Stock · 61,728 shares Expires 2019-11-24 F1 · security: The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018. F4 · security: In accordance with Rule 16b-3, in advance of the effectuation of the transactions reported, the issuer's board of directors approved an amendment to the convertible note held by the reporting person who is a director and 10% beneficial owner of the issuer. The amendment of the outstanding convertible note is reported as a cancellation of the "old" note and the grant of a replacement note. Read SEC document |
| May 10, 2018 Filed May 14, 2018 20:01 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantCommon Stock | 10,209 | $1.90 | $19,397.10 |
DisclosureSEC source: 0001493152-18-006784 · form4.xml · nonDerivative · entry 2 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 995,593 F1 · security: The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018. F3 · kind: The reporting person was issued common stock in lieu of accrued interest owed in connection with the convertible note described in Table II. Read SEC document |
| May 10, 2018 Filed May 14, 2018 20:01 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | Exercise / conversionCommon Stock | 263,158 | $1.90 | $500,000.20 |
DisclosureSEC source: 0001493152-18-006784 · form4.xml · nonDerivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 985,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018. F2 · kind: The reporting person was issued common stock in connection with the conversion of a convertible note, as amended, at $1.90 per share. See Table II for a description of the convertible note. Read SEC document |
| May 03, 2018 Filed May 7, 2018 22:21 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantCommon Stock | 420,737 | $1.90 | $799,400.30 |
DisclosureSEC source: 0001493152-18-006360 · form4.xml · nonDerivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 722,226 Read SEC document |
| November 24, 2017 Filed Dec 8, 2017 22:42 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | Grant8% Convertible Note · Derivative | 1,851,851 | $500,000.00 Strike: $0.27 | $925,925,500,000.00 |
DisclosureSEC source: 0001493152-17-014433 · form4.xml · derivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 1,851,851 Underlying: Common Stock · 1,851,851 shares Expires 2019-11-24 Read SEC document |
| July 11, 2017 Filed Jul 13, 2017 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,706,978 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001493152-17-007777 · form4.xml · derivative · entry 3 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,706,978 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2017 Filed Jul 13, 2017 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | Exercise / conversionCommon Stock | 1,706,978 | $0.05 | $80,227.97 |
DisclosureSEC source: 0001493152-17-007777 · form4.xml · nonDerivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,227,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 20:15 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantCommon Stock | 4,166,667 | $0.24 | $1,000,000.08 |
DisclosureSEC source: 0001493152-17-004329 · form4.xml · nonDerivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 9,044,717 F1 · kind: Represents a purchase meeting the requirements of Rule 16b-3. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:15 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | PurchaseCommon Stock | 4,878,050 | $0.41 | $2,000,000.50 |
DisclosureSEC source: 0001415889-16-007051 · form4-09062016_040905.xml · nonDerivative · entry 1 Schinazi Raymond F · CIK 0001397607 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 4,878,050 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.